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Abstract 
 
 
Autosomal dominant, missense mutations in the Leucine Rich Repeat protein Kinase 2 (LRRK2) 
gene are the most common genetic predisposition to develop Parkinson’s disease (PD). LRRK2 
kinase activity is increased in several pathogenic mutations [N1437H, R1441C/G/H, Y1699C, 
G2019S], implicating hyperphosphorylation of a substrate in the pathogenesis of disease. 
Identification of the downstream targets of LRRK2 is a crucial endeavor in the field to 
understand LRRK2 pathway dysfunction in disease. We have identified the signaling adapter 
protein p62/SQSTM1 as a novel endogenous interacting partner and substrate of LRRK2.    
Using mass spectrometry and phosphospecific antibodies, we found that LRRK2 
phosphorylates p62 on Thr138 in vitro and in cells. We found that the pathogenic LRRK2 PD 
associated mutations [N1437H, R1441C/G/H, Y1699C, G2019S] increase phosphorylation of 
p62 similar to previously reported substrate Rab proteins. Notably we found that the pathogenic 
I2020T mutation, nor the risk factor mutation displayed decreased phosphorylation of p62. p62 
phosphorylation by LRRK2 is blocked by treatment with selective LRRK2 inhibitors in cells. We 
also found that the amino terminus of LRRK2 is crucial for optimal phosphorylation of Rab7L1 
and p62 in cells. LRRK2 phosphorylation of Thr138 is dependent on a p62 functional ubiquitin 
binding domain at its carboxy terminus. Co-expression of p62 with LRRK2 G2019S increases 
the neurotoxicity of this mutation in a manner dependent on Thr138. p62 is an additional novel 
substrate of LRRK2 that regulates its toxic biology, reveals novel signaling nodes and can be 
used as a pharmacodynamic marker for LRRK2 kinase activity.   
 
 
 
  
3 
 
Introduction 
 Parkinson’s disease (PD) is a progressive neurodegenerative disorder with no known 
cure. PD is typically of idiopathic origin; however, it has been established that environmental 
exposures to toxins and inheritance of dominant or recessive mutations can precipitate the 
onset of disease. The neuropathological hallmark of Parkinson’s disease is the presence of 
cytoplasmic alpha-synuclein inclusions (1,2). Cytoplasmic proteinaceous toxic aggregates are 
common features of multiple neurodegenerative disorders. Selective autophagy directs the 
clearance of aggregated proteins and dysfunctional organelles and it is thought that this process 
is necessary for handling these toxic aggregates. It is likely that autophagic handling of 
dysfunctional or aggregated proteins is disrupted in neurodegenerative diseases, and could be 
due to deregulation of protein chaperones or autophagy adapter proteins.  
The adapter protein p62/sequestosome-1 (p62) is a component of cytoplasmic ubiquitin 
positive inclusions in PD and several protein aggregation based neurological disorders (3-11). 
The p62 protein has multiple characterized domains (12-14) including a PB1 domain (N’-Phos 
and Bem1 domain) that enables self-oligomerization and binds signaling molecules, an LC3 
interaction region (LIR) and a ubiquitin binding domain (UBA) through which p62 binds 
ubiquitinated protein aggregates for sequestration and formation of the autophagosome. Other 
protein interaction domains are a TRAF6 binding domain (TB), nuclear import and export 
signals (NLS and NES), a KEAP interaction region (KIR) and a zinc finger domain (ZZ). p62 
itself is an autophagy substrate and inhibition of autophagy machinery causes accumulation and 
oligomerization of p62 (15-17). The several functions and pathologies of p62 function are 
regulated by posttranslational modifications such as ubiquitination and phosphorylation (15,18).  
p62 activity bridges autophagy to the stress response pathway through regulation of the 
interaction of KEAP with Nrf2 to promote its stability and gene activation. This interaction is 
regulated by p62 phosphorylation at Ser349 by mammalian target of rapamycin complex 1 
(mTORC1), Casein kinase 1 (CK1), and TAK1 (19-21). p62 facilitates the removal of 
intracellular organelles dependent on activation and phosphorylation by TBK1 on Ser403 
(22,23). CK2 also regulates Ser403 increasing affinity for ubiquitin to regulate the selective 
clearance of ubiquitinated proteins (24). ULK1 phosphorylation of Ser407 regulates 
phosphorylation of Ser403 in an interplay of autophagy kinases (25). Additionally, p62 is 
phosphorylated by CDK1 at Thr269 (26), and p38G phosphorylation of p62 Thr269 is necessary 
for amino acid dependent activation of mTORC1 (27). PB1 domain interaction partner selection 
can be regulated by phosphorylation by PKA on Ser24 (28).  
Autosomal dominant, missense mutations in the Leucine Rich Repeat protein Kinase 2 
(LRRK2) gene are a genetic predisposition to develop Parkinson’s disease (PD) (29-33). 
LRRK2 mutations account for approximately 1-5% of familial and sporadic PD and are inherited 
with an autosomal dominant pattern with incomplete penetrance (34-39). The most common 
mutation leads to a serine substitution of Gly2019 in subdomain VII of the kinase domain (36), 
which increases kinase activity 2-4 fold (40-42). Other pathogenic inherited mutations in the 
Roc/COR domain (R1441G/C/H, Y1699C, and N1437H), also result in increased kinase activity, 
but are dephosphorylated at Ser910/935/955/973 (43). It is currently unknown how pathogenic 
mutations in LRRK2 across its multiple domains cause PD. Inhibition of LRRK2 kinase activity 
and several pathogenic LRRK2 mutations have been shown to alter LRRK2 protein complexes, 
with a dynamic loss and gain of binding partners, and redistribution within the cell.  
Interestingly, cytoplasmic aggregates of LRRK2 expressed in cell culture and primary 
neurons co-localize with p62 (44,45). Further, over-expression of LRRK2 induces the 
accumulation of p62 (46,47), while LRRK2 knockouts similarly increase p62 accumulation 
(48,49), indicating a potential signaling axis for LRRK2 in regulating autophagy. LRRK2 has 
been associated with dysfunctions in multiple cellular processes (50) for example translation 
(51,52), mitochondrial health (53-56), vesicular trafficking and autophagy (45,57-66), 
cytoskeletal organization(67-72), WNT signaling (73,74), NFAT signaling (75) and inflammation.  
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Endogenous LRRK2 phosphorylation of a subset of Rabs implicates LRRK2 function in 
vesicular trafficking and autophagy (58). Several studies link LRRK2 function to autophagy, 
however the mechanism of how enhanced kinase activity, through mutation, alters protein 
degradation pathways has yet to be validated. However, LRRK2 kinase inhibition stimulates 
autophagy in several systems, implicating substrate modification in the process (76-78).  
Interestingly, it was reported that activated Nrf2 relieves some of the neuronal toxicity presented 
by overexpression of mutant LRRK2 (79), and p62 links autophagy and the Nrf pathway(19,80). 
In an attempt to identify a novel mechanism of LRRK2 function in stress response and 
autophagy, we investigated the functional interaction of LRRK2 with p62. We confirmed the 
interaction of LRRK2 and p62, and mapped the reciprocal sites of interaction in cells and in 
vitro. Proteins in complex with kinases are also sometimes substrates for these enzymes, and 
we found that p62 is phosphorylated by LRRK2 in a manner that depends on the LRRK2 amino 
terminus and phosphorylation on Ser910/935.  LRRK2 [G2019S] neuronal toxicity is enhanced 
by co-expression with p62 in a manner dependent on Thr138.  These data have important 
implications for the role of LRRK2 in neuronal stress response and death through the regulation 
of p62 (81).   
 
Materials and Methods 
Buffers, chemicals and antibodies. 
Lysis Buffer contained 50 mM Tris/HCl, pH 7.4, 1 mM EGTA, 1 mM EDTA, 1 mM sodium 
orthovanadate, 10 mM sodium β-glycerolphosphate, 50 mM NaF, 5 mM sodium pyrophosphate, 
0.27 M sucrose, 1 mM Benzamidine and 1 mM phenylmethanesulphonylfluoride (PMSF) and 
was supplemented with Sigma Protease Inhibitor Cocktail (Sigma) and ROCHE PhosStop 
(Roche). Detergents used in the lysis buffer are 1% Triton X-100 or 1% NP40. Lysis buffer used 
for endogenous p62/SQSTM1 pThr138 detection was supplemented with 0.15M NaCl and 0.5% 
NP40.  Buffer A contained 50 mM Tris/HCl, pH 7.4, 50 mM NaCl, 0.1 mM EGTA and 0.27 M 
sucrose. Proximity Ligation Assay reagents were from Duolink. LRRK2 kinase inhibitor 
GNE1023 was described in (44) and synthesized at Genentech and provided by Genentech; 
PF475 was described in (82) and purchased from Sigma. Anti-GFP (clones 7.1 and 13.1) and 
anti-HA (clone 3F10) antibody are bought from Roche. Beta-actin (D6A8) and Hsp90 (C45G5) 
were from Cell Signaling Technologies. Anti LRRK2 (N241) is from Neuromab. Anti LRRK2 
pSer935 (UDD2) and anti LRRK2 pSer1292 were from Abcam. Rabbit polyclonal anti-p62 
phosphothreonine 138 antibody was generated by injection of the KLH conjugated 
phosphopeptide NGPVVGpTRYKC*SV (where pT is phosphothreonine and * indicates KLH 
conjugation site) into rabbits and was affinity purified by positive and negative selection against 
the phospho and de-phospho peptides respectively at Yenzym Inc. Anti phosphothreonine 138 
was used at a final concentration of 1Pg/mL in the presence of 10Pg/mL non-phosphorylated 
peptide. Mouse anti-p62 (M162-3), rabbit anti-p62 (PM045), and rat anti-phospho-p62 Ser403 
(D343-3) are from MBL. FLAG M2 antibody was purchased from Sigma. Mouse anti-E3 tubulin 
(Tuj1) was from Biolegend (Covance). Rabbit anti-active caspase-3 was from R&D Systems. 
Sheep anti-phospho Rab8, sheep anti-phospho Rab10, and sheep anti-phospho Rab7L1 were 
kind gifts from Professor Dario Alessi (MRC-PPU, University of Dundee, Scotland).  Anti-GFP 
for immunoblotting was from Roche (clones 7.1 and 13.1) or rabbit monoclonal anti-GFP from 
LifeTechnologies was used for PLA. GFP-Trap Agarose was purchased from Chromotek. 
Calyculin A and Okadaic acid were from LC Labs, and MLi-2 (83) was a kind gift of Professor 
Dario Alessi (MRC-PPU, University of Dundee, Scotland). 
 
Cell culture, treatments and cell lysis 
Tissue culture reagents were from Life Technologies or Thermo Scientific. HEK-293 
cells (from ATCC) were cultured in Dulbecco's Modified Eagle's medium supplemented with 
10% FBS, 2mM glutamine and 1×antimycotic/antibiotic solution. The Flp-in T-REx system was 
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from Invitrogen and stable cell lines were generated as per manufacturer instructions by 
selection with hygromycin as has been described previously (Nichols et al., 2010;Doggett et al., 
2012). T-REx cell lines were cultured in DMEM supplemented with 10% FBS and 2mM 
glutamine, 1X antimycotic/antibiotic and 15 µg/ml Blasticidin and 100 µg/ml hygromycin. The 
treatments were added as indicated time and concentration. Human lung alveolar epithelial 
A549 cells (from ATCC) were cultured in DME/F-12 with L-Glutamine and 10% FBS, 1x 
antimycotic/antibiotic. Human control lymphoblasts were a kind gift of Dr. Birgitt Schuele (The 
Parkinson’s Institute, Sunnyvale CA) and cultured in RPMI supplemented with L-glutamine and 
10%FBS, 1x antimycotic/antibiotic and 1x non-essential amino acid (Gibco). Mouse embryonic 
fibroblasts (MEFs) were cultured in DMEM supplemented with L-glutamine and 10%FBS, 1x 
antimycotic/antibiotic and 1x non-essential amino acid (Gibco). HEK293 and T-REx were 
transfected by the polyethylenimine method (84) and were lysed 48 hours after transfection. T-
REx cultures were induced to express the indicated protein by inclusion of 1 µg/ml doxycycline 
in the culture medium for 48 hours. After the indicated culture conditions, cell lysates were 
prepared by washing once with PBS and lysing in situ with 0.4 ml of lysis buffer per 10cm dish 
on ice, then centrifuged at 15,000 x g at 4 °C for 15 minutes. Protein concentrations were 
determined using the Bradford method with BSA as the standard.  Generation and culture of 
CRISPR/Cas9 GFP-LRRK2 H1299 cells can be found in the Supplemental Figure 1.  
 
DNA Constructs 
Restriction enzyme digests, DNA ligations and other recombinant DNA procedures were 
performed using standard protocols with Fermentas enzymes. DNA constructs used for 
transfection were purified from Escherichia coli DH5D using Qiagen plasmid Maxi kits according 
to the manufacturer's protocol. The pcDNA5-Frt-FLAG-LRRK2 and pcDNA5-Frt-GFP LRRK2 
constructs, and pcDNA5-Frt-FLAG-LRRK1 used for transfections were provided by Professor 
Dario Alessi (MRC-PPU, University of Dundee, Scotland). The LRRK2 cDNA was sub-cloned 
from pcDNA3.1 (Melachroinou et al., 2016) into the pcms-EGFP reporter plasmid, expressing 
un-tagged LRRK2 and EGFP under separate promoters; or, into pcDNA3.1 with a C-terminal c-
myc epitope tag. A plasmid encoding HA-tagged p62 was obtained from Addgene (plasmid 
#28027) and was subcloned into pcDNA5-Frt-FLAG and pGEX6P. pFLAG HDAC4 was a gift 
from Eric Verdin (Addgene plasmid #13821), pcDNA3 IKKH FLAG was a gift from Tom Maniatis 
(Addgene plasmid #26201), HDAC6 Flag was a gift from Eric Verdin (Addgene plasmid 
#13823), Harm Kampinga provided pcDNA5/FRT/TO-V5 HSPA1A (Addgene plasmid #19510), 
pcDNA5/FRT/TO-V5 HSPH1 (Addgene plasmid #19506) pcDNA5/FRT/TO-V5 HSPA8 
(Addgene plasmid #19514), pcDNA5/FRT/TO-V5 DNAJB6b (Addgene plasmid #19528), 
pcDNA5/FRT/TO-V5 DNAJB1 (Addgene plasmid #63102) and pcDNA5/FRT/TO-V5 DNAJB8 
(Addgene plasmid #19531). Hsp90 was a gift from William Sessa (Addgene plasmid #22487), 
pcDNA5-Frt-GFP-Rab7L1 was synthesized using codon optimization by GeneArt 
(ThermoScientific). DNA manipulations were carried out using standard techniques and 
mutagenesis was performed with the GeneArt mutagenesis kit (ThermoScientific).  
 
Immunoprecipitation Assays 
For transfected HEK293 or T-REx cells, cell lysates were prepared in Lysis buffer (0.4ml 
per 10cm dish) and subjected to immunoprecipitation with anti-FLAG M2 agarose or GFP-Trap 
A beads (Chromotek) at 4°C for 2 hours. Beads were washed twice with Lysis Buffer 
supplemented with 300mM NaCl, then twice with Buffer A. Immune complexes were incubated 
at 70°C for 10 minutes in LDS sample buffer, passed through a Spin-X column (Corning) to 
separate the eluate from the beads, then boiled. Equal amounts of immunoprecipitated protein 
were subjected to western blots with indicated antibodies. For endogenous LRRK2 
immunoprecipitation, mouse anti-LRRK2 (N241; Neuromab) non-covalently conjugated to 
protein-G agarose (1µg antibody: 1µL bead) was used to enrich LRRK2 protein complexes from 
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A549 cells. Endogenous p62/SQSTM1 was immunoprecipitated by mouse anti-p62 (MBL) from 
human lymphoblastoid cells covalently conjugated to protein-A sepharose (1µg antibody: 1µL 
bead; Perce Crosslink IP Kit, ThermoScientific) and incubated at 4°C for 4 hours. The 
immunoprecipitated samples were analyzed by immunoblotting. 
 
Protein Purifications 
To induce the expression of GST-p62, E. coli BL21 Rosetta transformants of pGEX-6P plasmids 
harboring p62 or mutant p62 were grown to a OD600 of 0.5 at 37◦C and induced at 30◦C for 3 
hours by the addition of IPTG (isopropylβ-D-thiogalactoside) to a final concentration of 1 mM. 
Cells were lysed by sonication in lysis buffer with 1% (v/v) Triton X-100 and 0.1% beta-
mercaptoethanol. The soluble fraction was retrieved by centrifugation at 15000 g for 15 min. 
Recombinant protein was purified by glutathione–Sepharose chromatography, and proteins 
were eluted in buffer A with 20 mM glutathione, 1 mM benzamidine and 2 mM PMSF, or were 
liberated from the GST fusion by incubation with 0.1mg of precision protease per 1mg of 
protein. 
  
Kinase assays  
For assays using recombinant proteins as substrates, the reactions were set up in a total 
volume of 25 µl with recombinant kinase (GST-LRRK2970-2527 or FLAG-LRRK21-2527) in 50mM 
Tris pH 7.5, 0.1mM EGTA, 10 mM MgCl2 and 0.1 mM [J-32P] ATP (~500cpm/pmol), with p62 
substrate, with the indicated concentrations of enzyme and substrate. After incubation for 30 
min at 30°C, the reactions were stopped by the addition of Laemelli sample buffer. Reaction 
products were resolved by electrophoresis on NuPage Bis-Tris gels and stained with coomassie 
blue. The incorporation of phosphate into protein substrates was determined by 
autoradiography and/or immunoblotting with phosphospecific antibodies. Kinase reactions for 
mass spectrometry based phosphosite identification were carried out under similar conditions 
but with 200mM cold ATP and reactions were resolved by electrophoresis on NuPage Bis-Tris 
gels and stained with colloidal blue and p62 was excised and submitted for MS analysis at MS 
Bioworks.  
 
Mass spectrometry  
Sample Preparation and LC/MS/MS. Replicate gel segments were reduced using dithiothreitol, 
alkylated with iodoacetamide and then subjected to digestion with trypsin, chymotrypsin and 
elastase (Promega, Madison, WI). Digests were analyzed by nano LC/MS/MS with a 
NanoAcquity HPLC system (Waters, MA) interfaced to a Q Exactive tandem mass spectrometer 
(ThermoFisher, San Jose, CA). Peptides were loaded on a trapping column and eluted over a 
75µm analytical column at 350nL/min; both columns were packed with Jupiter Proteo resin 
(Phenomenex, Torrance, CA). A 30 min gradient was employed for each digest. The mass 
spectrometer was operated in data-dependent mode, with MS and MS/MS performed in the 
Orbitrap at 70,000 and 17,500FWHM resolution, respectively. The fifteen most abundant ions 
were selected for MS/MS from each MS scan. Dynamic exclusion and repeat settings ensured 
each ion was selected only once and excluded for 30s thereafter. 
 
Database searching. Product ion data were searched against the combined forward and reverse 
protein database using a locally stored copy of the Mascot search engine v2.5 (Matrix Science, 
London, U.K.) via Mascot Daemon v2.5. Peak lists were generated using Proteome Discoverer 
v1.4 (ThermoFisher). The database was appended with common background proteins. Search 
parameters were precursor mass tolerance 10 ppm, product ion mass tolerance 0.02 Da, 2 
missed cleavages allowed, fully tryptic peptides only for trypsin and no enzyme specificity for 
chymotrypsin and elastase, fixed modification of carbamidomethyl cysteine, variable 
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modifications of oxidized methionine, protein N-terminal acetylation, pyro-glutamic acid on N-
terminal glutamine and phosphorylation on serine, threonine and tyrosine.  
 
Data Analysis. Mascot search result flat files (DAT) were parsed to the Scaffold software v3.1 
(Proteome Software, Portland, OR) to create a non-redundant list per sample. The criteria for 
accepting a protein identification were determined by calculating the false discovery rates (FDR) 
from the concatenated forward/reverse database. This resulted in the following cutoff values: 
90% protein and 50% peptide level probability (probabilities were assigned by the Protein 
Prophet algorithm), and a minimum of two unique peptides per protein. These criteria resulted in 
FDR of less than 1% at the protein level.  
 
Immunocytochemistry and Proximity Ligation Assay (PLA) 
For immunocytochemistry, cells were grown on coverslips and washed with PBS and fixed with 
4% paraformaldehyde for 15 min, followed by two wash steps with PBS. After permeabilization 
for 5 min with PBST, a 30 min blocking step with 10% goat serum (Dako cytomation) in PBS 
was performed. This was followed by 2 hrs incubation with FLAG M2 antibody in PBS. After 
three washes with PBS for 5 min, the cells were incubated for 1 h with secondary antibody 
(Alexa Fluor® -conjugated antibody, 1:500 dilution, Molecular Probes) and washed three times 
for 5 min with PBS. PLAs were performed on eight-well CC2 chamber slides. Cells were fixed 
and permeabilized as in the immunocytochemistry experiments, then blocked with Duolink 
Blocking Solution for 30 min at 37 ◦C. Immediately after blocking, the cells were incubated with 
the indicated primary antibodies in the Duolink Antibody Diluent for 1 h at room temperature 
(20–24 ◦C). The cells were washed twice with Duolink Wash Buffer A for 5 min before the 
incubation of the PLUS and MINUS PLA probes. The cells were incubated with PLA probes for 
1 h at 37 ◦C, followed by two washes with Wash Buffer A for 5 min. The cells were then 
incubated with pre-mixed Ligation-Ligase solution at 37 ◦C for 30 min. After two washes with 
Wash Buffer A for 2 min, the cells were incubated with pre-mixed Amplification-Polymerase 
solution for 60–90 min at 37 ◦C. Finally, the cells were washed twice with Duolink Wash Buffer B 
for 10 min, followed by 0.01 × Wash Buffer B for 1min. The slides were dried in the dark and 
mounted with Duolink II Mounting Medium. The images were taken by Nikon Eclipse TI 
florescence microscope and quantified by Duolink ImageTool (Version 1.0.1.2), around 150 
cells signal were counted for each sample. The quantification data was graphed by Prism5 
(GraphPad), and statistics was calculated by one way ANOVAs. The quantification of the PLA 
results was from 3 independent experiments.  
 
Primary Neuronal Survival Assays 
Primary rat embryonic cortical neurons were prepared as described (Melachroinou et al., 2016). 
Briefly, embryonic day 17 rat cortices were dissociated in trypsin/DNAse followed by gentle 
mechanical disruption. Dissociated neurons were plated at a density of approximately 125,000 
cells per cm2 in complete Neurobasal medium with l-glutamine, penicillin/streptomycin, and B-27 
serum free supplements (all components from Thermo Scientific). On day four following plating, 
the neurons were transiently transfected with un-tagged human LRRK2 (WT or G2019S) cDNA 
in pcms-EGFP expression vector using Lipofectamine 2000 (Thermo Scientific) as described 
previously (85), together with FLAG-tagged p62 (WT or T138A) at a ratio of 3:1 with LRRK2 in 
excess. Three days following transfection, the neurons were fixed in 4% paraformaldehyde, and 
processed for anti-LRRK2 (MJFF c41-2) or anti-FLAG/anti-GFP immunofluorescence, with DAPI 
as a nuclear counterstain. Co-expression of p62 and LRRK2 within individual neurons, 
transfected with an excess of LRRK2 cDNA, was confirmed by co-immunostaining for anti-Flag 
and anti-LRRK2 (clone c41-2); and the neuronal phenotype of the cultures was established by 
triple immunostaining for anti-GFP, anti-Flag, and anti-E3 tubulin. The stained coverslips were 
observed under 40X magnification, and neurons double positive for EGFP and FLAG were 
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scored according to their nuclear morphology. Neurons were considered to be apoptotic if two 
or more condensed chromatin bodies were observed within a neuronal profile. From at least 
four parallel coverslips (performed from 2 independent cultures), 100 positive neurons were 
counted by a researcher blind to the experimental conditions, and apoptotic neurons were 
expressed as a percentage of neurons positive for both FLAG and EGFP. Parallel coverslips 
were co-immunostained for anti-Flag and anti-active caspase-3, together with DAPI, as an 
additional marker of neurons undergoing apoptotic cell death.  
 
Results 
LRRK2 interacts with p62 
LRRK2 is known to interact with chaperone proteins Hsp90, Cdc37, Hsp70 and Hsc70 
(64,86-88). These chaperones are necessary for proper folding of proteins. Since cytoplasmic 
accumulations of LRRK2 have been found coincident with p62, we sought to survey several 
protein chaperones involved in post-translational protein handling. Using epitope tag 
immunoprecipitations we screened a panel of protein chaperones for interaction with LRRK2 
using plasmid based expression in T-REx 293-GFP or T-REx 293-GFP-LRRK2 cells. We tested 
the signaling chaperone Hsp27, along with the protein folding chaperones DNAJB6 (Hsp40), 
DNAJB8 (Hsp40), HSPA1A (Hsp70), HspA8 (Hsc70), Hsp90, HSPH1 (Hsp110), and also 
HDAC6 and p62 which are autophagy related proteins that can shuttle cargo to aggresomes or 
autophagosomes. We found that LRRK2 interacts with all of these chaperones in this 
expression system, as well as p62 and HDAC6, except for Hsp110, Figure 1A. To determine 
spatial proximity of LRRK2 and p62 in cells, we performed the in situ Proximity Ligation Assay 
[PLA] on cells expressing GFP-LRRK2 and FLAG-p62, Supp. Figure 2A. We compared the 
number of signals per p62/LRRK2 co-transfected cell to the number of signals per cell 
transfected with cytoplasmic HDAC4 or vector alone and found a significant and specific 
increase in p62-LRRK2 signals (representative micrographs in Supp. Figure 2A and B). 
LRRK2 and its paralog LRRK1 harbor similar domain structure, and both could therefore 
interact with p62. We asked if p62 could interact with LRRK2 or LRRK1 in co-expression 
analyses. FLAG-tagged LRRK2 or LRRK1 were expressed with HA-p62, and anti-FLAG 
immunoprecipitates were analyzed for the presence of p62. LRRK1 has also been associated 
with autophagy, (89).  Figure 1B shows that only p62 was highly enriched in LRRK2 immune-
complexes, with a slight increase in the presence of LRRK2 inhibitor GNE1023.   
  We next sought to isolate endogenous LRRK2/p62 complexes. To do this, we tested two 
cell lines and immunoprecipitation methods. We first immunoprecipitated endogenous LRRK2 
immunoprecipitates from A549 cells and found endogenous p62 present, Figure 1C, where 
inclusion of LRRK2 inhibitor resulted in a slight increase in the levels of p62 in the 
immunoprecipitate.  Since we observed slight increases in p62-LRRK2 complexes in cells after 
LRRK2 inhibition, we sought to quantitate this interaction with the selective inhibitor MLi2 and 
found a reproducible, but modest increase in p62 co-precipitation with inhibited LRRK2, Supp. 
Figure 2C. We next employed the PLA on A549 cells to ask if endogenous LRRK2 and p62 
were in close spatial proximity. Using specific antibodies against LRRK2 and p62, we found 
significant numbers of PLA signals for LRRK2/p62 complexes over IgG controls and significantly 
more PLA signals when treated with LRRK2 inhibitor for 90min, Supp. Figure 2D. To 
complement our endogenous interaction data with another immunological retrieval tool, We next 
expressed amino-terminal tagged GFP-LRRK2 from a Bacmam virus and 24 hours after 
infection cells were fixed at 0, 30min and 3hrs after treatment with LRRK2 inhibitor, Supp. 
Figure 2E. After acute LRRK2 inhibition or in mutants that are dephosphorylated at Ser910/935 
(e.g. R1441C/G/H and Y1699C) LRRK2 forms skein or punctate structures in the cytoplasm of 
cells.  Staining for endogenous p62 revealed an increase in co-localization with LRRK2 skeins 
and puncta over time.  Using CRISPR/Cas9, we generated an H1299 cell line targeted with 
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GFP at the endogenous start-codon of LRRK2 to confirm interaction of LRRK2 and p62 with an 
alternate tag and cell background, described in Supplemental Figure 1. We found that 
endogenous GFP-LRRK2 interacts with p62. Together, these data show that LRRK2 and p62 
interact and confirm previously reported data from Park et al, showing endogenous interaction 
(62).  
 
Identification of the p62 and LRRK2 Interaction Domains 
 LRRK2 and p62 are multi-domain proteins with several protein interaction regions. In 
order to provide insight on downstream biology of the interaction, we determined the interaction 
domain of p62 on LRRK2 and the interaction domain of LRRK2 on p62 using deletion plasmid 
constructs. To identify the LRRK2 interaction domain with p62, we expressed GFP-tagged 
LRRK2 fragments (Figure 2A) and analyzed GFP immunoprecipitates for endogenous p62, 
Figure 2B; GFP-tagged LRRK2 is still competent to bind p62 (Figure 1D). The amino terminal 
armadillo and ankyrin repeat domains of LRRK2 are required for interaction with p62. 
Fragments of p62 (Figure 2C) were expressed in cells expressing GFP-LRRK2 or GFP, and we 
asked which FLAG-tagged p62 fragments co-precipitated with LRRK2 in GFP 
immunoprecipitates. We found that the PB1 domain fragment aa1-125 did not interact with 
LRRK2 when expressed alone, however fragments of p62 that included aa125-225 did interact 
with LRRK2. We also found that p62118-440 but not p62167-440 precipitated with LRRK2, indicating 
the ZZ domain [aa118-167] is necessary for interaction with LRRK2 Figure 2D. We next sought 
to determine if this is a direct interaction using recombinant p62 and LRRK2. FLAG-tagged 
p62118-225 was unstable when expressed in cells, precluding conclusions about interaction using 
this approach.  We did however ask if full-length recombinant FLAG-tagged LRRK2 could be 
isolated with bacterially expressed full-length p62 or the minimal p62 binding domain identified 
in Figure 2D [p62118-225]. GST or GST-p62 or GST p62118-225 were incubated with full-length 
LRRK2 and protein complexes were retrieved with glutathione sepharose and analyzed by 
immunoblot. We found that LRRK2 was co-precipitated with GST-p62 and GST-p62118-225, but 
not GST alone, Figure 2E.  
 
LRRK2 phosphorylates p62 on Thr138.  
 p62 is regulated by phosphorylation by Casein kinase 2, TBK1/IKKH, p38δ and ULK1 to 
regulate its cellular functions.  We therefore asked if LRRK2 not only bound p62, but could also 
phosphorylate it as well. Using recombinant p62 and recombinant LRRK2, our initial analysis 
indicated that LRRK2 could indeed phosphorylate p62.  In order to analyze p62 phosphorylation 
by LRRK2 and determine the phosphorylation site (s), recombinant p62 was expressed as a 
GST fusion protein and following purification on glutathione sepharose, the GST tag was 
removed by cleavage with precision protease. Full length recombinant LRRK2, purified from 
mammalian cells as an amino-terminal FLAG tagged protein, was used to phosphorylate p62 
(Figure 3A). Detailed OrbiTrap mass spectrometry analysis of in vitro kinase reaction products 
revealed several potential sites of phosphorylation. The table in Figure 3 shows the sites of 
phosphorylation cumulatively identified over several MS determinations (shown in Supp. Figure 
3) with A score and localization probabilities indicated and spectral counts for the number of 
times the peptide has been observed (Spc). Because LRRK2 binds p62 through its ZZ domain, 
we further investigated the sites identified within this domain and generated p62 phosphosite 
mutant T138A, T164A, S176A recombinant proteins. p62 T138A, T164A, T138A/T164A, S176A 
and T138A/T164A/S176A were subjected to in vitro kinase reactions with LRRK2970-2527 
[G2019S] recombinant protein. We found decreased LRRK2-mediated phosphorylation when 
Thr138 was substituted with Ala, while T164A and S176A had no impact (Supp. Figure 4), 
indicating that the Thr residue at position 138 is the likely site of LRRK2 modification. 
 
 
10 
 
Validation of LRRK2 phosphorylation of p62 Thr138 
We generated a phosphospecific antibody against phosphothreonine 138 (pThr138) to validate 
the mass spectrometry phosphosite analyses and track p62 modification.  This antibody is 
specific for the phosphoThr138 peptide, and does not detect dephospho-peptide as shown in 
Supp. Figure 4B. To test this antibody on p62, we compared p62 to p62 T138A 
phosphorylation by LRRK2970-2527 [G2019S] recombinant protein in the presence or absence of 
LRRK2 inhibitor GNE1023 (Figure 3B, left panel) and full length LRRK21-2527 and kinase inactive 
LRRK21-2527 [D1994A] (Figure 3B, right panel). Similar to Supp. Figure 4, we found that LRRK2 
preferentially phosphorylates Thr138. Our antibody specifically recognizes p62 phosphorylated 
at Thr138 by LRRK2 on wild-type p62 but neither on p62 T138A nor in reactions where inactive 
LRRK2 or LRRK2 inhibitor was included. We tracked LRRK2 kinase activity with a pThr1491 
antibody, which reveals LRRK2 autophosphorylation kinase activity was absent in the presence 
of the kinase inactive mutant D1994A.  
 
LRRK2 Phosphorylates p62 in cells 
 Thus far, we have found that LRRK2 forms an endogenous complex with p62 in cells 
and that LRRK2 can phosphorylate p62 in vitro.  We next sought to determine if LRRK2 could 
phosphorylate p62 in cells and if inhibition of LRRK2 would suppress p62 phosphorylation at 
Thr138.  We examined the dose effects of MLi-2 inhibition of LRRK2 in cells expressing GFP-
LRRK2 [WT, D2017A, and G2019S] and FLAG-p62 [WT and T138A]. We found that, similar to 
the bone fide Rab GTPase substrates, concentrations of 3-30nM MLi-2 decreased p62 
phosphorylation at T138A, Figure 4A. We tracked the effects of the potent LRRK2 inhibitor with 
pSer935 and pSer1292 antibodies; dephosphorylation of the autophosphorylation site (Ser1292) 
and the upstream kinase site (Ser935) were concomitant with p62 dephosphorylation. We 
observed a similar reduction in p62 phosphorylation using two other structurally diverse 
inhibitors, PF745 and GNE1023, with IC50 values below 100nM, compared to an IC50 of below 
10nM for MLi-2 (Supp. Figure 5 A and B). We used MLi-2 on control EBV-transformed 
lymphoblasts to ask if inhibition of endogenous LRRK2 activity blocks endogenous p62 
phosphorylation at pThr138. We found that 10nM MLi-2 reduces the phospho Thr138 signal on 
p62 immunoprecipitates (Figure 4B), demonstrating p62 is an endogenous substrate of LRRK2. 
We next compared the rate of dephosphorylation of LRRK2 and p62 pThr138 after inhibition 
with MLi-2. We found that LRRK2 autophosphorylation is reduced within 10 minutes, while 
pSer935 and pThr138 is ablated by 40 minutes (Figure 4C). To verify LRRK2 inhibitor treatment 
was specific to blocking LRRK2 activity, we employed the A2016T mutation of LRRK2 which 
shows reduced sensitivity to LRRK2 inhibitors.  Treatment of cells expressing p62 and wild-type 
LRRK2 with MLi-2 showed reduced p62 phosphorylation but not treatment of cells expressing 
A2016T with p62, Figure 4D.  
The dephosphorylation of p62 Thr138 is rapid, revealing a phosphatase activity against 
this site. In order to determine if PP1 or PP2 type phosphatases are responsible for p62 
dephosphorylation, we employed a pharmacological approach using Okadaic acid to inhibit PP2 
and Calyculin A to inhibit PP1. Previously, we showed that Calyculin A prevents LRRK2 inhibitor 
induced dephosphorylation (81). Figure 5 shows that inclusion of 100nM Okadaic acid does not 
affect p62 dephosphorylation in the presence of 10nM MLi-2, while 20nM Calyculin A enhances 
p62 phosphorylation on its own, and also prevents dephosphorylation when co-treated with 
10nM MLi-2 for 30 minutes, implicating PP1-type and not PP2-type phosphatases in the 
dephosphorylation of LRRK2 phosphorylated p62. 
     
A Subset of Pathogenic PD-Associated LRRK2 Mutations Enhance p62 Phosphorylation 
Pathogenic PD mutations found in the Roc/COR and kinase domains exhibit increased kinase 
activity in cells, as measured by autophosphorylation of pSer1292 and phosphorylation of 
downstream Rab GTPase substrates. Since we found that LRRK2 phosphorylates p62 in cells 
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and discovered p62 to be a bone fide substrate of LRRK2, we next investigated if pathogenic 
PD mutations modulate p62 phosphorylation similar to what has been reported for LRRK2 
kinase activity in vitro and against Rabs in cells. To do this, we expressed GFP-LRRK2 [WT, 
N1437H, R1441G, Y1699C, G2385R, and G2019S] and FLAG-p62 WT in cells and analyzed 
p62 phosphorylation, Figure 6A. Immunoblotting with anti-pThr138 antibody, we found Thr138 
phosphorylation was only observed with active LRRK2 mutants and dramatically reduced in 
GFP vector control or kinase inactive LRRK2 (D2017A). LRRK2 N1437H, R1441G, Y1699C and 
G2019S display increased p62 Thr138 phosphorylation, compared to wild-type kinase, Figure 
6A and quantitated in Figure 6B. We observed increased kinase activity in N1437H, R1441G, 
Y1699C and G2019S LRRK2 in cells with the pSer1292 antibody, similar to the increase in p62 
phosphorylation. We observed decreased kinase activity of I2020T and G2385R LRRK2 by 
pSer1292 and p62 pThr138 immunoblotting, which reflects previous analyses of these LRRK2 
mutants (90,91). In line with similar reports, LRRK2 pSer935 is decreased in N1437H, R1441G, 
Y1699C, and G2385R.  
There are discrepancies between the observed increased kinase activity of Roc/COR 
mutants (e.g. R1441C/G, Y1699C) in vivo and lack thereof in vitro.  Increased pSer1292 and 
Rab phosphorylation is observed in cells, where only slight increases in activity on peptide 
substrates (Nictide and LRRKtide) or native protein substrates (Rabs) are found in vitro 
(58,90,91).  We therefore asked if the phosphorylation pattern of p62 was similar in vitro with the 
same LRRK2 mutants. We used full-length recombinant LRRK2 proteins harboring the R1441G, 
Y1699C, G2019S, and G2385R mutations and compared phosphorylation of recombinant, tag-
free p62 protein and recombinant tag-free Rab8 for in vitro kinase assays. As was observed 
previously for the Rab substrates (58), we observed increased phosphorylation with LRRK2 
G2019S and diminished phosphorylation with the G2385R mutation, while we observed similar 
phosphorylation of p62 by R1441G and Y1699C compared to wild-type protein, Figure 6C. 
Given that these mutations show similar activity as wild-type protein in vitro, but increased 
activity in cells, these results indicate that the increased activity of the Roc/COR mutations 
observed in cells could be mediated by a cellular factor or event as proposed in (58). 
 
LRRK2 Amino Terminus is required for optimal substrate phosphorylation 
We mapped the interaction domain of LRRK2 and p62 to the amino terminus of LRRK2 
and the ZZ domain of p62. We therefore examined whether structural deletions of the LRRK2 
interaction domain with p62 would impact regulation of p62. We tested LRRK21-2527, LRRK2970-
2527, and LRRK21326-2527, all shown to be active in their recombinant form, for their ability to 
phosphorylate p62 in cells. We found that deletion of the LRRK2 amino terminus ablates p62 
phosphorylation by LRRK2970-2527 and LRRK21326-2527 proteins, Figure 7A. We next asked if the 
amino terminus is similarly needed to regulate Rab substrates Rab7L1, Rab8 and Rab10.  
LRRK2 phosphorylation of Rab7L1 tracked similar to p62, where both LRRK2970-2527 and 
LRRK21326-2527 did not phosphorylate Rab7L1 at Thr71, Figure 7B left panel. Interestingly, 
LRRK2970-2527 was able to phosphorylate both Rab8 and Rab10, though LRRK21326-2527 was 
unable to modify these Rabs, Figure 7B middle and right panels. These data further implicate 
the amino terminus of LRRK2 in regulation of its kinase activity against certain substrates. Ito et 
al. showed that blocking LRRK2 phosphorylation at Ser935 significantly reduced Rab10 
phosphorylation (92); we therefore determined whether regulation of the crucial phosphorylation 
sites Ser910/935 is involved in p62 regulation. To investigate this, we expressed p62 in cells 
expressing WT, D2017A, and S910/935A LRRK2, and found that although S910/935A is active 
[pSer1292], it does not phosphorylate p62, Figure 7C.  
 
The Carboxy Terminus of p62 Influences its Phosphorylation by LRRK2  
A previous report indicates that there is interplay in the regulation of pSer407 and pSer403 in 
p62. We therefore wanted to understand if there could be any impact of the carboxy terminus or 
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its phospho-regulatory sites on the phosphorylation of p62 by LRRK2. This was accomplished 
by mutating these sites to alanine or phosphomimetic glutamate and asking if this would alter 
LRRK2 phosphorylation of Thr138. We saw that neither S403A or S407A alanine substitutions 
nor the phospho-mimetic glutamate substitutions, S403E (which also cross-reacts with anti-
pSer403 antibodies) or S407E significantly altered LRRK2 G2019S phosphorylation on Thr138, 
Figure 8A. However, removing the ability of p62 to bind ubiquitin blocked Thr138 
phosphorylation. Phe406 in the UBA domain of p62 is crucial for ubiquitin binding and we found 
that substitution of Phe406 with Valine, a mutation known to reduce ubiquitin binding to p62 
(25,93), decreased the LRRK2 phosphorylation of p62 Thr138, Figure 8A.  Similarly, when we 
deleted the UBA domain we also reduced p62 phosphorylation at Thr138, Figure 8B, despite 
maintaining its interaction with LRRK2, Figure 2.  
 
p62 Contributes to LRRK2-mediated Neuronal Cell Death  
Expression of PD associated mutants of LRRK2 in primary neuronal cultures induces cell 
toxicity including neurite shortening and apoptosis (60,94-98). To determine if p62 contributes to 
mutant LRRK2 induced neuronal cell toxicity, we expressed wild-type LRRK2 or mutant LRRK2 
[G2019S] with p62 or p62 T138A, Supplemental Figure 6 and Figure 9. We observed intense 
colocalization of LRRK2 with p62 and condensed nuclei, Figure 9A.  The classical apoptotic 
nuclear morphology co-localized with activated caspase-3 immunostaining, Figure 9A (red). 
When these cells were scored for the percentage of transfected neurons exhibiting condensed 
nuclear morphology, we found that G2019S increases the percentage of cells with condensed 
nuclei that stain positive for caspase 3, over wild-type LRRK2 or p62 expression alone. 
However, the LRRK2 unphosphorylatable mutant p62 Thr138Ala fails to enhance the toxicity of 
mutant LRRK2, Figure 9B. Representative image of neuronal culture purity as indicated by EIII-
Tubulin staining is shown in Figure 9C. Additional representative images of neurons expressing 
p62 (and LRRK2), and labeled for active caspase-3 are shown in Supplemental Figure 7. Here 
we show that co-expression of LRRK2 [G2019S] with p62 significantly increases the number of 
apoptotic neurons.  
 
Discussion 
 
Almost 15 years after the LRRK2 locus was found to be associated with Parkinson’s 
disease, only a subset of  endogenous substrates have been highly validated in the field 
(51,58,99), namely the Rab GTPases. In the present study, we contribute another protein to this 
repertoire of LRRK2 substrates, the signaling adapter p62/SQSTM1. We showed that p62 is an 
endogenous interactor of LRRK2. Using mass spectrometry and mutational analysis, we found 
that LRRK2 phosphorylates p62 on Thr138 in vitro. Using a specific pThr138 antibody that 
readily detects p62 phosphorylated on Thr138, we then showed that p62 phosphorylation is 
diminished in cells treated with specific and selective LRRK2 inhibitors and that PD associated 
mutations in LRRK2 (N1437H, R1441G, Y1699C and G2019S) increase p62 phosphorylation. 
The precise mechanism of how p62 Thr138 phosphorylation alters its downstream function in 
established pathways is still to be investigated.  However, we report here that when p62 and 
mutant LRRK2 are introduced together in primary neurons, a synergistic lethality is observed 
with increased apoptosis (Figure 9), which is rescued by mutation of Thr138 to Ala.   
 We originally observed p62 association with LRRK2 in a targeted screen of multiple 
putative interacting chaperone and adapter proteins. Hsp27 provides thermotolerance and 
stabilization of denatured protein for remedy by refolding chaperones (100,101), and interacts 
with LRRK2.  We and others have previously identified Hsp90 and Cdc37 interacting with 
LRRK2 (86,87,102-105). Hsp70 and Hsc70 are also known LRRK2 interacting proteins (64). 
Expression of Hsp110, a protein disaggregase alone did not interact with LRRK2. HDAC6 and 
p62 facilitate the removal of aggregated and ubiquitinated proteins and interestingly, these 
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proteins specifically co-immunoprecipitated with LRRK2. LRRK2 was recently reported to 
interact with acetylated microtubules, which are produced by enhanced HDAC6 activity (106), 
supporting LRRK2 as playing a regulatory role for HDAC6.  Endogenous LRRK2 interacts with 
endogenous p62, and the specificity of this interaction is demonstrated by the more selective 
co-immunoprecipitation with LRRK2 instead of LRRK1, Figure 1. LRRK1 domain structure is 
very similar between LRRK2 and LRRK1, except for divergent amino termini. This likely 
explains the identification of the LRRK2 amino terminus as the interaction domain with p62 
[Figure 2]. We additionally found that p62 binds to the LRRK2 armadillo domain through its ZZ 
domain [p62118-225], which is similar to what was seen in Park et al. 2016 (62). There is overlap 
in the conclusion but a slight discrepancy in the results, which could be due to the use of 
internal deletion constructs (62) versus expression tagged fragments used here. Typically, we 
observe an enhanced interaction of LRRK2 and p62 in the presence of LRRK2 inhibitors, 
however this may be context dependent or transient.  
 Some kinases interact with their substrates stably (107) and this is true for LRRK2 and 
p62. We mapped Thr138 on p62 as a specific site of LRRK2 phosphorylation, and we 
developed phospho-specific antibodies against this site. Interestingly, a tryptic peptide from p62 
that encompasses the Thr138 site has been identified in multiple studies (108-111) but with di-
Gly linkage on the Lys at the +3 position from Thr138; this could have precluded or complicated 
identification of pThr138 in unbiased phospho-proteomic screens and increased our technical 
difficulty in detecting endogenous pThr138.  We established a dependence of LRRK2 activity for 
phosphorylation of p62 Thr138 in cells using three structurally distinct inhibitors. Using the 
specific inhibitor MLi-2, LRRK2 phosphorylation of p62 was blocked within 40 minutes, and was 
restored with the inhibitor resistant mutant [A2016T]. Importantly, we found that inhibition of 
endogenous LRRK2 decreased p62 phosphorylation on Thr138 in lymphoblasts (Figure 4B). 
Having established that blocking LRRK2 kinase activity results in decreased p62 
phosphorylation, we next characterized the in vivo phosphatase activity on p62.  The 
downstream target p62 was dephosphorylated at a similar IC50, but at a more rapid rate than 
pSer1292 (Figure 4). The rapid dephosphorylation of p62 indicates that a phosphatase actively 
regulates p62. The LRRK2 signaling pathway has been implicated to involve PP1 and possibly 
PP2A, (112) in the role of Ser935 dephosphorylation. Using a pharmacological approach, we 
narrowed the class of phosphatases involved in p62 Thr138 dephosphorylation to PP1-type 
enzymes, and possibly PP2A (Figure 5).   
We found that pathogenic PD-associated LRRK2 mutants [N1437H, R1441G, Y1699C 
and G2019S] enhance the phosphorylation of p62 in cells. However, this enhancement was only 
observed with G2019S in vitro, compared to the R1441G and Y1699C mutants. This reflects 
similar modification patterns observed with the recently reported Rab substrates comparing in 
vitro to in vivo activity of LRRK2 (58). This could be due to cellular factors or localization 
differences in cells that are not present in vitro, that contribute to the regulation of LRRK2 kinase 
activity. The risk factor mutation G2385R, which was reported to have decreased activity and 
reduced Ser935 phosphorylation (103), exhibited reduced phosphorylation of p62 in cells and in 
vitro, similar to the Rab substrates, Figure 6. We observed that the I2020T mutation did not 
increase LRRK2 phosphorylation of p62, raising important distinctions in biochemical changes 
caused by different disease or risk enhancing mutations. These data indicate that, similar to 
pSer935 and phospho-Rab substrates, p62 pThr138 is a viable pharmacodynamic marker and 
activity marker for LRRK2.  
There is yet to be a crystal structure of full-length LRRK2; however, a molecular model, 
derived from cryo-EM and cross-linking studies, provides useful insight into the general 
organization of the dimer (113), with other structural studies in general support (114,115). The 
amino terminus appears to lay across the Roc-COR domain interface to regulate activity. In 
support of this, Ito et al determined that phosphorylation of LRRK2 pSer910/935 is necessary 
for Rab 10 phosphorylation(92). In the context of the novel substrate p62, we found that 
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pSer910/935 is also necessary for p62 Thr138 phosphorylation. Using LRRK2 amino terminal 
deletion mutants, we showed that the amino terminus influences phosphorylation of p62 and 
Rab substrates. It is therefore likely that phosphoregulation of the LRRK2 amino terminus (e.g. 
Ser910/935/955/973) indirectly regulates LRRK2 substrate phosphorylation and therefore the 
kinases and phosphatases that modify LRRK2 are prime targets for elucidation. This is distinct 
from in vitro conditions (Figure 3), where LRRK2970-2527 is able to phosphorylate p62, but it is 
however further reflective of the differences in LRRK2 kinase activity observed in vitro versus in 
cells as is seen with Roc/COR mutants.  This is also the case for the Rab proteins, where 
LRRK2970-2527 is able to phosphorylate Rabs in vitro (58), but pSer910/pSer935 are required in 
cells (92).  
 There are consistent reports of LRRK2 modulation of the autophagic process. However, 
the mechanistic role of LRRK2 in regulating autophagy has been elusive to date, i.e. no 
members of the autophagic machinery (i.e. ATG proteins) have been shown to be validated 
LRRK2 kinase substrates. p62 is phosphorylated by multiple kinases throughout several 
domains to regulate its function and many of these phosphorylation events have been shown to 
have interdependent regulation. We show that the carboxy terminal ubiquitin binding domain of 
p62 influences the phosphorylation of the ZZ domain by LRRK2. It is therefore possible that the 
ubiquitin binding function of p62, a crucial aspect of its autophagic role, feeds into LRRK2 
regulation of p62 and thus autophagy. Therefore, the ubiquitin binding function of p62 bridges 
LRRK2 activity to autophagy regulation, where the impact of hyperphosphorylation of p62 will 
need to be investigated. 
Our data linking p62 to LRRK2 Parkinson’s disease supports previous reports of p62 
involvement with aggregated DSyn protein inclusions in PD as well as in other 
neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), polyglutamate 
disorders, and multiple system atrophy (MSA) (3-11). p62 binds to synuclein inclusions and 
pathology increases in the contralateral hemisphere from fibrillar DSyn injection (116). This 
places p62 intracellularly with endogenous DSyn and also inclusions in cells affected by 
synuclein through uptake from the extracellular milieu. Interestingly, cytoplasmic aggregates of 
LRRK2 expressed in cell culture and primary neurons colocalize with p62 (44). Furthermore, 
p62 knockout in a DSyn transgenic mouse has been found to increase Lewy body like pathology 
(117). 
p62 is involved in multiple cellular processes that could indeed intersect with reported 
functions of LRRK2, from mitochondrial maintenance to vesicular trafficking 
(12,13,15,18,46,62,63,65,118-125).  For LRRK2, expression of PD associated mutants in 
cultured neurons leads to enhanced cell toxicity (61,94,95). When we asked if p62 modulated 
this phenotype we indeed found a synergistic toxic effect of mutant LRRK2 and p62 expression, 
dependent on Thr138 (Figure 9). It is possible that in this context, over-expressed 
hyperphosphorylated p62, co-expressed with G2019S-LRRK2, fails to activate the Nrf2 
cytoprotective pathway similar to that recently reported in cultured neurons in which elevated 
levels of phosphorylated p62 (at Ser351) are observed following proteasome inhibition (126). In 
fact, it was recently shown that upregulating Nrf activity decreased LRRK2 neuronal toxicity 
(79). We have identified a cooperative role of p62 in LRRK2 kinase activity dependent toxicity, 
but delineating the effects on other p62 functions are the topics of future studies. The interplay 
of p62 phosphorylation on disease pathogenesis is only now being uncovered and indeed, there 
are other LRRK2 influenced phosphorylation sites (62), further linking the phosphoregulation of 
p62 to PD. In conclusion, this work identifies p62 as a novel substrate of LRRK2. With this novel 
substrate we validate the necessity of the amino terminus for LRRK2 substrate phosphorylation 
and uncover p62 as a potential mediator of PD-mutant LRRK2 toxicity. (127,128) 
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Figure Legends 
Figure1. LRRK2 interacts with p62/SQSTM1.  
(A) Plasmids encoding V5-tagged Hsp27, DNAJB6 (Hsp40), DNAJB8 (Hsp40), HSPA1A 
(Hsp70), HspA8 (Hsc70), Hsp90, HSPH1 (Hsp110) and FLAG-tagged HDAC6 and FLAG-p62 
were transfected into GFP or GFP-LRRK2 wild-type T-REx HEK293 cells. GFP 
immunoprecipitates from 1% NP40 soluble cell lysates were subjected to immunoblot with D-
GFP, D-V5 (chaperones) and D-FLAG (HDAC6 and p62). (B) HA-p62 was co-expressed with 
FLAG vector, FLAG-LRRK2 or FLAG-LRRK1 in HEK293 cells. 48hrs post-transfection, cells 
were treated with GNE1023 for 90min and D-FLAG immunoprecipitates were blotted with D-HA 
(p62), D-FLAG (LRRK2/LRRK1) D-Hsp90 and D-LRRK2 pSer935 and pSer1292. Lower panel 
LiCOR quantitation of the D-HA/D-FLAG signals set to LRRK2, no inhibitor control; n=3 one 
sample t-test set to the hypothetical value of 1, *p ≤ 0.05 (C) A549 cells treated ± 2PM GNE1023 
were subjected to LRRK2 immunoprecipitation with D-LRRK2 (UDD3) and immunoprecipitates 
were subjected to immunoblot with D-LRRK2 (N241, pSer1292 and pSer935) and D-p62. (D) 
Endogenous GFP-LRRK2 H1299 cell lines generated by CRISPR/Cas9 editing were subjected 
to GFP-Trap immunoprecipitation; Lysates and immunoprecipitates were blotted for the 
presence of LRRK2, p62, Hsp90 and 14-3-3 proteins.  Generation of CRISPR/Cas9 lines 
described in Supplemental material.  
 
Fig 2. Interaction Domains of p62/SQSTM1 and LRRK2.  
Structures and the deletion constructs of LRRK2 (A) and p62/SQSTM1 (C) are shown. B. 
LRRK2 interaction domains with p62/SQSTM1.  HEK293 cells were transfected with indicated 
GFP tagged LRRK2 constructs. GFP-TRAP immunoprecipitates were immunoblotted for 
endogenous p62 (D-p62), and Hsp90. Binding of endogenous p62/SQSTM1 is represented 
qualitatively in A with – or +. (D) GFP or GFP-LRRK2 WT T-REx cells were transfected with 
indicated FLAG tagged p62/SQSTM1 fragment constructs. 48hrs after transfection, cells were 
harvested and subject to GFP-IP as described. GFP antibody showed the loading quantity of 
GFP-LRRK2. FLAG antibody indicated the amount of expressed FLAG-p62/SQSTM1 pulled 
down by GFP-LRRK2. The binding ability of expressed p62/SQSTM1 fragments were presented 
with – or + in C. (E) LRRK2 and p62/SQSTM1 interacts in cell free context. In in vitro binding 
assay, bacterially expressed GST, GST-p62/SQSTM1 full length or GST-p62/SQSTM1118-225 
were incubated with full length FLAG-LRRK2 G2019S. The protein complexes were retrieved 
with glutathione sepharose and immunoblotted for LRRK2 (N241). GST blots indicate GST, 
GST p62/SQSTM1 full length or fragment bait retrieved. 
 
Figure 3. Identification of residues on p62 phosphorylated by LRRK2.  
(A) E. coli expressed p621-440 (2.5PM) was reacted with 200nM full length LRRK21-2527 [G2019S] 
in vitro with cold ATP.  The colloidal blue stained band corresponding to p62 was excised and 
analyzed by Orbitrap mass spectrometry. The table presents the total number of peptide 
spectral counts identified from 10 individual reactions, along with the best A score and 
localization probability (129) for each site. Extended results from individual reactions and MS 
analyses are in Supplemental Figure 2. (B) Left panel, 3 PM recombinant wild type p62 or 
T138A were reacted with 93nM LRRK2970-2527 in the absence or presence of 1PM GNE1023 with 
[J-32P]-ATP. Right panel, 3 PM recombinant wild type p62 or p62 [T138A] were reacted with 
56nM full length LRRK21-2527 G2019S or kinase inactive LRRK21-2527 [D1994A]. Reaction 
products were analyzed by coomassie blue staining, autoradiography and immunoblot using 
anti-p62 pThr138 immunoblot (DpThr138). LRRK2 kinase activity was tracked with (DpThr1491) 
antibodies and DLRRK2 (N241).  
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Figure 4. LRRK2 phosphorylates p62 Thr138 in cells.   
(A). GFP, GFP-LRRK2 wildtype, kinase inactive [D2017A] or G2019S were expressed along 
with FLAG-p62 or FLAG-p62 T138A in HEK293.  Cells were treated with the indicated 
concentrations of MLi-2 (0-30nM) for 90 minutes. Equal amounts of anti-FLAG 
immunoprecipitates were analyzed by pThr138 and p62 immunoblot. Cell lysates were probed 
for LRRK2 (DGFP and N241), phospho-LRRK2 (DpSer1292 and DpSer935) and actin. (B) 
Human EBV-transformed Lymphoblasts were grown in suspension and treated with 10nM MLi-2 
(90min). Endogenous p62 immunoprecipitates from monoclonal Dp62 (MBL) IPs were analyzed 
by DpThr138, DpSer403 and total Dp62. Lysates were probed for total and phosphorylated 
LRRK2 (DN241/DpSer935), p62 and actin. (C) Wild-type GFP-LRRK2 was expressed with 
FLAG-p62 and treated for the indicated times with 10nM MLi-2 and analyzed as in (A). (D) T-
REx lines harboring the indicated LRRK2 variants (GFP-LRRK2 WT, kinase inactive [D2017A] 
or LRRK2 [A2016T]) were transfected with FLAG-tagged p62 WT or p62 T138A and induced 
with 1Pg/mL doxycycline for 48 hours and treated ± 10nM MLi-2 for 90min prior to harvest. p62 
immunoprecipitates were analyzed for pThr138 as in A and C.  
 
Figure 5. p62 pThr138 is regulated by a Calyculin A sensitive phosphatase.   
Cells co-expressing GFP, GFP-LRRK2, or GFP-LRRK2 G2019S and wild-type FLAG-p62 were 
treated with 10nm MLi-2, 100nm Okadaic acid alone or simultaneously with 10nm MLi-2 for 30 
min (left panel). In the right panel, cells co-expressing GFP, GFP-LRRK2, or GFP-LRRK2 
G2019S and wild-type FLAG-p62 were treated with 10nm MLi-2, 20nm Calyculin A alone or 
simultaneously with 10nm MLi-2 for 30 min. Anti-FLAG immunoprecipitates were analyzed for 
changes in p62 phosphorylation by DpThr138 immunoblot.  LRRK2 phosphorylation responded 
as was previously reported with the antibodies for total LRRK2 (DGFP and N241) and phospho-
LRRK2 (DpSer1292 and DpSer935).   
 
Figure 6. Effects of pathogenic PD-associated LRRK2 mutations on p62 phosphorylation 
in cells and in vitro.   
(A) Plasmids encoding GFP, GFP-LRRK2 [N1437H, R1441G, Y1699C, G2019S, I2020T and 
G2385R] PD mutations were transfected along with FLAG-p62 wild-type in HEK293 cells.  Anti-
FLAG immunoprecipitates were analyzed for changes in p62 phosphorylation by DpThr138 
immunoblot. LRRK2 phosphorylation was assessed by immunoblot with total LRRK2 (DGFP 
and N241) and phospho-LRRK2 (DpSer1292 and DpSer935).  (B) Quantification of the 
phosphorylation change is expressed as the ratio of phosphorylated p62 at Thr138 over total 
p62 signal as analyzed via LiCor Odyssey and normalized to wild-type LRRK2. n=3, 
means±s.e.m. (C) 35nM full- length recombinant LRRK2 [WT, D1994A, R1441G, Y1699C, 
G2019S, and G2385R] was reacted with 3PM p62 or Rab8 and with [J-32P]-ATP. Reaction 
products were analyzed by coomassie blue staining, autoradiography and immunoblot with anti-
p62 pThr138 immunoblot (DpThr138), rabbit total p62 (MBL), sheep anti-phospho Rab8 and 
total Rab8 (CST). LRRK2 kinase activity was tracked with DpThr1491 and total LRRK2 was 
detected with DLRRK2 (N241). 
 
Figure 7. The LRRK2 amino terminus and Ser910/935 phosphorylation are required for 
optimal substrate phosphorylation. (A) Full length GFP-LRRK2 WT and D2017A (KD), GFP-
LRRK2970-2527 and GFP-LRRK21326-2527 were co-expressed with FLAG-p62 wild-type or FLAG-
p62 T138A, in the presence or absence of 10nM MLi-2. FLAG immunoprecipitates were probed 
for p62 pThr138 and lysates were blotted for LRRK2 (N241) and phospho-LRRK2 DpSer1292 
and DpSer935 (B) Full length GFP-LRRK2 WT and D2017A (KD), GFP-LRRK2970-2527 and GFP-
LRRK21326-2527 were co-expressed with Rab7L1 (left panel), Rab8A (middle panel) or Rab10 
(right panel) and their indicated variants. Cell lysates were probed for phospho-Rab7L1 Thr71, 
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phospho-Rab8 Thr72, and phospho-Rab10 Thr73, or total LRRK2 (N241) and phospho-LRRK2 
(DpSer1292 and DpSer935). (C) FLAG-tagged p62 WT was expressed in T-REx HEK293 cells 
stably expressing GFP, GFP-LRRK2 WT, GFP-LRRK2 D2017A, and GFP-LRRK2 [S910/935A] 
and cells were simultaneously induced to express LRRK2 by inclusion of 1Pg/mL doxycycline in 
the culture media. Cells were treated ±10nm M-Li2 for 90 minutes prior to harvest. FLAG 
immunoprecipitates were probed for p62 pThr138 and lysates were blotted for LRRK2 (N241) 
and phospho-LRRK2 DpSer1292 and DpSer935. 
 
Figure 8.  The p62 UBA domain is necessary for LRRK2 phosphorylation at Thr138. 
(A) The indicated p62 mutants were transiently expressed in HEK293 cells along with either 
GFP-LRRK2 WT, FLAG-IKKH, GFP-LRRK2 kinase dead (KD) [D2017A], or GFP-LRRK2 
G2019S. FLAG immunoprecipitates were probed for p62 pThr138 and pSer403. Lysates were 
blotted for LRRK2 (N241), phospho-LRRK2 DpSer1292 and DpSer935, and actin. (B) FLAG-
p62 WT, FLAG-p62 F406V, or FLAG-p62 [aa1-380] were co-expressed with GFP-LRRK2 WT 
and GFP-LRRK2 G2019S in HEK293 cells and analyzed as in A. 
 
Figure 9. p62 participates in mutant LRRK2-induced neuronal death signaling. (A) Primary 
rat embryonic cortical neurons, prepared as in Supplemental Figure 5, were co-immunostained 
for anti-Flag (green) and anti-active caspase-3 (red), together with DAPI (blue). (B) The stained 
coverslips were observed under 40X magnification, and neurons double positive for EGFP and 
FLAG were scored according to their nuclear morphology. Neurons were considered to be 
apoptotic if two or more condensed chromatin bodies were observed within a neuronal profile. 
100 positive neurons in each experiment were counted by a blinded rater, and apoptotic 
neurons were expressed as a percentage of neurons positive for both FLAG and EGFP. mean 
±s.e.m. N=3, one-way ANOVA with Tukey’s post-hoc test; P*<0.05, P***<0.001. (C) Parallel 
coverslips of primary rat cortical neurons were co-transfected with LRRK2 (pcms-EGFP) and 
Flag-p62, and the fixed cultures stained for mouse anti-EIII-Tubulin (Tuj-1; red) and rabbit anti-
Flag (magenta), with DAPI (blue). Images were obtained on a Leica TSP5 confocal microscope. 
 
Supplemental Figure 1. (A) General scheme of locus and repair template. (B) Genomic DNA 
from 4 targeted clones and two scrambled clones were amplified with the primers surrounding 
the cleavage site PCR products were analyzed by gel electrophoresis. Variable lengths of 
targeted loci are found compared to no insertions from the scrambled gRNA control lines.  
 
Supplemental Figure 2. Detection of LRRK2:p62 complexes by PLA.  (A) FLAG vector, 
FLAG-HDAC4 or FLAG-p62/SQSTM1 were transfected into T-REx WT GFP-LRRK2 cells.  In 
situ Proximity Ligation Assay (PLA) assay was performed using D-GFP (LRRK2) and D-FLAG 
(p62 or HDAC4). The top panel shows PLA signals in GFP-LRRK2/FLAG-p62 expressing cells 
with single antibody GFP or FLAG controls. The bottom left-hand panels show the merged 
image of cells stained with DAPI (blue) and ligation amplifications (red). A merged image of 
GFP-LRRK2 with DAPI/PLA is presented in the middle column. PLA signals per cell were 
quantitated by Duolink ImageTool and are presented as fold change from the number of vector 
signals per cell from n=3 experiments. Results are means± s.e.m., analysis was one-way 
ANOVA against each control (*P < 0.05). The right-hand panels show immunocytochemistry 
(ICC) with anti-FLAG antibody staining of transfected HDAC4 or p62. The merged image shows 
DNA (blue), GFP–LRRK2 (green) and FLAG–HDAC4 or p62 (red). (B) Representative negative 
control images of T-REx cells subjected to PLA. The top two rows show merged images of PLA 
signal detection (Red) in GFP-LRRK2 expressing T-REx cells (green) transfected with FLAG-
p62/SQSTM1 or FLAG-HDAC4. PLA was carried out with only one primary antibody (indicated). 
The bottom left image shows signal detection in LRRK2 absent cells with both GFP and FLAG 
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antibodies. Signals from these controls are included with the quantitation graph of PLA 
signals/cell from Figure 1B in the bottom right. (C) A549 cells treated ± 0.1PM MLi2 at different 
times, for four hours, were subjected to LRRK2 immunoprecipitation with D-LRRK2 (UDD3) and 
immunoprecipitates were subjected to immunoblot with D-LRRK2 (N241 and pSer935) and 
mouse D-p62 (MBL). D-p62/D-LRRK2 LiCOR quantitation is shown in the lower panel; t-test, 
*p≤0.05. (D) PLA was performed on A549 cells treated ± 2PM GNE1023 using control rabbit and 
mouse IgG, D-p62 (MBL) and D-LRRK2 (N241). Results are means± s.e.m., analysis was one-
way ANOVA against each control. The representative images of PLA in A549 cells are shown. 
Images in the top row show single antibody PLA reactions along with IgG control pair antibody. 
The bottom row includes both anti-LRRK2 (N241) and mouse anti-p62 antibodies. The bottom 
right panel shows signals from PLA on human lung alveolar epithelial A549 culture treated with 
2PM GNE1023 for 1.5hrs. (E) A549 cells were transduced with GFP-LRRK2 Bacmam, 24 hrs 
before GNE1023 (2PM) treatment.  Cells were fixed at indicated times following GNE1023 
treatment and probed with a SQSTM1/p62 antibody. p62 relocalizes from punctate structures to 
LRRK2 skeins and inclusions following GNE1023 treatment.  
 
Supplemental Figure 3. In vitro phosphorylation and Mass Spectrometry Mapping of p62 
pThr138 phosphorylation by LRRK2. (A) Carboxy terminal 6XHis-tagged p6285-440 3PM was 
reacted with 140nM Full length LRRK2 wild-type, kinase inactive LRRK2 [D1994A], and LRRK2 
[G2019S] or LRRK2970-2527 [G2019S] in vitro with cold ATP. The colloidal blue stained band 
corresponding to p62 was excised and analyzed by Orbitrap mass spectrometry.  The table 
presents the total number of peptide spectral counts for each of the reactions, along with the 
best A score and localization probability (Beausoleil et al. 2006) for each site. (B) 140nM 
LRRK21-2527 [G2019S] was reacted with 2PM GST-tagged p621-440, p621-380, p62118-225, or 140nM 
LRRK2970-2527 [G2019S] was reacted with 2PM p621-440 or p62118-225. The colloidal blue stained 
band corresponding to p62 was excised and analyzed by Orbitrap mass spectrometry.  (C) 
Reaction and mass spectral counts from Figure 3A reaction with 140nM kinase and 2.5PM p62.  
The colloidal blue stained band corresponding to p62 was excised and analyzed by Orbitrap 
mass spectrometry.  (D-F) Representative mass spectra observed from major potential 
phosphorylation sites identified in the ZZ domain of p62 for pThr138, pThr164 and pSer176.   
 
Supplemental Figure 4. Verification of pThr138 phosphosite by mutagenesis. A. 140nM 
LRRK2970-2527 [G2019S] was reacted with recombinant GST-tagged p62 wild-type, p62 [T138A], 
p62 [T164A], p62 [T138A/T164A] double mutant, p62 [S176A], and the p62 
[T138A/T164A/S176A] triple mutant at 3PM as indicated. Reaction products were resolved by 
SDS-PAGE and subjected to coomassie blue staining (lower panel) and autoradiography (upper 
panel). B. Phospho-Thr138 and dephosphopeptide were spotted with the indicated amount of 
peptide and immunoblotted with the anti-phosphoTHr138 antibody.  
 
Supplemental Figure 5. PF475 and GNE1023 inhibit p62 phosphorylation by LRRK2.  
(A). GFP, GFP-LRRK2 wildtype, kinase inactive [D2017A] or G2019S were expressed along 
with FLAG-p62 or FLAG-p62 T138A in HEK293 cells.  Cells were treated with the indicated 
concentrations of PF475 (0-3PM) for 90 minutes.  Anti-FLAG immunoprecipitates were analyzed 
by pThr138 and p62 immunoblot. Cell lysates were probed for LRRK2 (DGFP and N241), 
phospho-LRRK2 (DpSer1292 and DpSer935) and actin. (B). GFP, GFP-LRRK2 wildtype, kinase 
inactive [D2017A] or G2019S were expressed along with FLAG-p62 or p62 T138A in HEK293 
cells.  Cells were treated with the indicated concentrations of GNE1023 (0-3PM) for 90 minutes.  
Anti-FLAG immunoprecipitates were analyzed by pThr138 and p62 immunoblot. Cell lysates 
were probed for LRRK2 (DGFP and N241), phospho-LRRK2 (DpSer1292 and DpSer935) and 
actin. 
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Supplemental Figure 6. Primary rat embryonic cortical neurons were transfected on day four in 
vitro with un-tagged human LRRK2 (WT or G2019S) in pCMS-EGFP together with FLAG-
tagged p62 (WT or T138A) at a ratio of 3:1 with LRRK2 in excess, as described [53]. Three 
days post-transfection, neurons were fixed and processed for anti-LRRK2 (c41-2) anti-
FLAG/GFP immunofluorescence, with DAPI as a nuclear counterstain. (A) Top panel-
Representative images of LRRK2 and p62 signals from LRRK2/p62 expression with normal 
nucleus. Bottom panel-representative image of LRRK2 [G2019S]/GFP signal with apoptotic 
neucleus. (B&C) Representative apoptotic nuclei from LRRK2 [G2019S]/p62 and LRRK2 
[G2019S]/p62Thr138Ala, respectively.  
 
Supplemental Figure 7. Further representative images of caspase-3 staining in LRRK2 and 
p62 co-transfected neurons as in Figure 9. 
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  Supplemental Figure 1 

(A)  
Generation of CRISPR/Cas9 cell lines. :HXWLOL]HGWKH&5,635&DVV\VWHPWRLnVHUWH*)3LnWRWKHHnGRJHnRXV/55.
ORFXVRI+FHOOVYLD WKHKRPRORJ\GLUHFWHGUHSDLUSDWKZD\7KUHHJXLGHVHTXHnFHVZLWK ORZRIIWDUJHWVFRUHVZHUH
LGHnWLILHGZLWKLnWKH/55.VWDUWFRGRnUHJLRn&RPSOHPHnWDU\ROLJRVZLWK%EV,FRPSDWLEOHRYHUKDnJVZHUHGHVLJnHGIRU
HDFKWDUJHWVHTXHnFHSKRVSKRU\ODWHGDnnHDOHGWRHDFKRWKHUDnGWKHnOLJDWHGLnWR%EV,GLJHVWHGSODVPLGS6S&DV%%
$3XUR 3;9 $GGJHnHSODVPLGDFFRUGLnJ WR $VDnHJDWLYHFRnWUROZHJHnHUDWHGDSODVPLG
FRnWDLnLnJD6FUDPEOHVHTXHnFH*&$&7$&&$*$*&7$$&7&$7KHUHSDLUWHPSODWHGHVFULEHGLn(BZDVDES
'1$IUDJPHnWFRnVLVWLnJRIWKHOHIWKRPRORJ\DUPESRIHnGRJHnRXV/55.VHTXHnFHHnGLnJULJKWDIWHUWKH$7*
VWDUWFRGRnIROORZHGLnIUDPHE\WKHH*)3VHTXHnFHD****6OLnNHUDnGWKHULJKWKRPRORJ\DUPDnRWKHUESRI
HnGRJHnRXV/55.VHTXHnFHEHJLnnLnJDIWHUWKH$7*VWDUWFRGRn
*HnRPLF FOHDYDJH GHWHFWLRn DnDO\VLV LnGLFDWHG WKDW WKH IROORZLnJ JXLGH VHTXHnFH 
J&ATG*&7$*7**&$*&7*7&ZKHUH WKH LnLWLDWLnJPHWKLRnLnH LV Ln LWDOLFVZDVPRVWHIILFLHnW Ln LnWURGXFLnJGRXEOH
VWUDnGHG EUHDNV Ln + FHOOV DnG WKHUHIRUH ZDV VHOHFWHG IRU WKH JHnHUDWLRn RI WKH FHOO OLnH + FHOOV DW a
FRnIOXHnF\ZHUHFRWUDnVIHFWHGLnDVL[ZHOOSODWHZLWKPJ&5,635&DVSODVPLG/55.RU6FUDPEOHDnGPJ
UHSDLUWHPSODWHXVLnJ/LSRIHFWDPLnH/LIH7HFKnRORJLHVDFFRUGLnJWRWKHPDnXIDFWXUHU
VLnVWUXFWLRnVIROORZHGE\D
KLnFXEDWLRnLn530,PHGLXPVXSSOHPHnWHGZLWK)%6P0/JOXWDPLnHP0+(3(6DnGP0VRGLXP
S\UXYDWH0HGLXPZDVWKHnUHSODFHGZLWKIUHVKPHGLXPVXSSOHPHnWHGZLWKPJPOSXURP\FLn$IWHUIRXUGD\VRISXURP\FLn
VHOHFWLRnWKHPHGLXPZDVUHSODFHGDJDLnZLWKIUHVKPHGLXPZLWKRXWSXURP\FLn(LJKWGD\VODWHUFHOOVZHUHGLVVRFLDWHG
DnGVLnJOHFORnHVZHUHLVRODWHGE\VHULDOGLOXWLRnVLnWRZHOOSODWHV$IWHUWKUHHZHHNVRIH[SDnVLRnFORnHVZHUH
KDUYHVWHG DnG VFUHHnHG IRU WKH SUHVHnFH RI *)3 E\ LPPXnREORWWLnJ *)3SRVLWLYH FORnHV ZHUH IXUWKHU DnDO\]HG E\
VHTXHnFLnJ)RUWKLVSXUSRVHJHnRPLF'1$ZDVLVRODWHGXVLnJWKH'1HDV\7LVVXH.LWIURP4,$*(13&5ZDVSHUIRUPHG
XVLnJ.2'+RW6WDUW'1$3RO\PHUDVH1RYDJHnZLWKSULPHUV
&&*&$**$7&&&&**&7**&***7&*&**
DnG

*7&$*$**77&&7&$$*&&$$$7777***
WRDPSOLI\WKHWDUJHWORFXVESIUDJPHnWDPSOLILHGRnHnGRJHnRXV
ORFXVRUESIUDJPHnWDPSOLILHGRnPRGLILHG ORFXVVKRZn LnC3&5SURGXFWVZHUHFORnHGXVLnJWKH=HUR%OXnW
72323&5&ORnLnJ.LWIRU6HTXHnFLnJ,nYLWURJHnDnGLnGLYLGXDOFORnHVZHUHVXEMHFWHGWRVHTXHnFLnJ1RWHWKDWVSHFWUDO
NDU\RW\SLnJLnGLFDWHGWKDW+FHOOVFRnWDLnVL[FRSLHVRIFKURPRVRPHRnZKLFKWKHKXPDn/55.JHnHLVORFDWHG
)RUELRFKHPLFDOFKDUDFWHUL]DWLRnZHXVHGDFHOOOLnHZLWKDESGHOHWLRnHnGLnJESXSVWUHDPRIWKHVWDUWFRGRn
RIWKHFRUUHFWO\LnVHUWHG*)3IXVLRn7KLVFORnHKDVDWOHDVWRnHPRGLILHGDnGRnHXnPRGLILHGDOOHOH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